Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

66.34 +3.22 (+5.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 470,735
Open 64.60
Bid (Size) 57.71 (1)
Ask (Size) 105.52 (2)
Prev. Close 63.12
Today's Range 63.94 - 67.16
52wk Range 43.46 - 116.60
Shares Outstanding 59,719,570
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter: 
Via Benzinga

Performance

YTD
-39.73%
-39.73%
1 Month
-8.07%
-8.07%
3 Month
+15.62%
+15.62%
6 Month
+1.42%
+1.42%
1 Year
-37.63%
-37.63%

More News

Read More
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC
Via NewMediaWire
Blueprint Medicines' Ayvakit 'Will Garner Approval' Despite Questions, This Analyst Says
Via Benzinga
Analyst Sees Deteriorated Treatment Effect Of Blueprint's Much Awaited Mastocytosis Data
Via Benzinga
Blueprint Medicines Corporation (NASDAQ:BPMC) Investor Notice: Investigation over Possible Violations of Securities Laws
Via SBWire
What 14 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Data From Blueprint Medicines' Blood Disorder Trial Fails To Lift Shares
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Blueprint Medicines: Q2 Earnings Insights
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
EQUITY ALERT: Rosen Law Firm Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation – BPMC
From Rosen Law Firm
Via Business Wire
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
Via Benzinga
U.S. Stocks Open Lower; Nasdaq Down 150 Points
Via Benzinga
Blueprint Medicines Stock Is Getting Hammered Wednesday: What's Happening?
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint
Via Investor's Business Daily
Blueprint Medicines Shares Fall After Topline Results From Late-Stage Neoplastic Disorder Study
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
A Preview Of Blueprint Medicines's Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.